Navigation Links
MiMedx Group Announces Temporary Trading Symbol Designation
Date:2/22/2010

ATLANTA, Feb. 22 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG) has received numerous inquiries regarding the temporary change of its symbol to "MDXGE.OB" rather than "MDXG.OB".  This resulted from the change of the Company's fiscal year to a calendar year, as reported on form 8-K filed December 21, 2009.  The matter has been resolved and the OTC:BB has advised the Company that its stock will resume trading under "MDXG.OB" on Tuesday, February 23. Until such time, as was the case today, the Company's shares may be traded using the temporary symbol.

About MiMedx Group, Inc.

MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company's assets include intellectual property protecting a collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting a novel durable hydrogel technology. The Company has received FDA clearance for its first durable hydrogel product, the Paradis Vaso Shield ™ indicated for use as a cover for vessels following anterior spinal surgery.

Important Note regarding forward-looking statements and risk factors. This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. These statements include those regarding the date on which its shares will resume trading under its former symbol. These risks and uncertainties include that the resumption may be delayed due to administrative issues . The risks and uncertainties also include the risk factors detailed in its Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended March 31, 2009, and its most recent Form 10-Q filed on November 16, 2009. The Company does not undertake to update its forward-looking statements.

SOURCE MiMedx Group, Inc.

Back to top
'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group, Inc. Adds Ronald G. Wallace to Board of Directors
2. MiMedx Group Announces Post-split Name Change
3. MiMedx Announces Brian J. Splan as President
4. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
5. Anpath Group, Inc. Announces Fiscal 2010 Third Quarter Results
6. Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split
7. Invida Selects LaVoie Group as Public Relations Agency of Record
8. Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
9. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
10. Danaher Completes Offer for Genetix Group plc
11. Lori Kahler Appointed President of The RC Insight Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... a distinguished life sciences expert with a proven track record in strategic global ... range of services related to laboratory testing and analysis for the pharmaceutical, medical ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a ... ) and the US National Institutes of Health. Continue ... ... ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led by ... in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The article ... coronary artery disease (CAD). Lam is an assistant professor at the Department of ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
Breaking Biology News(10 mins):